Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

2C-B: Difference between revisions

From Pharmacopedia
[checked revision][checked revision]
2C-B final link addendum (web-claude, consolidated): merge new links onto the citation-corrected page (5-HT2A/2C/2B receptors, monoamine transporter, Schedule I, Controlled Substances Act, Convention on Psychotropic Substances, Medicines Control Council, Ann Shulgin, Empathogens); psychostimulants house-term fix; propagate the lithium clinical correction into the interactions field
Repoint CYP2D6/CYP3A4 links to the new Enzyme: namespace
Line 164: Line 164:
* '''Lithium: seizure and severe-reaction risk.''' Lithium combined with psychedelics including 2C-B is associated with a markedly increased risk of seizures and severe adverse reactions; the mechanism is distinct from serotonin syndrome. Avoid combination.
* '''Lithium: seizure and severe-reaction risk.''' Lithium combined with psychedelics including 2C-B is associated with a markedly increased risk of seizures and severe adverse reactions; the mechanism is distinct from serotonin syndrome. Avoid combination.
* '''Psychostimulants: additive cardiovascular load.''' 2C-B itself produces modest sympathomimetic effects (elevated heart rate, mild blood pressure increase); concurrent psychostimulants compound the cardiovascular burden.
* '''Psychostimulants: additive cardiovascular load.''' 2C-B itself produces modest sympathomimetic effects (elevated heart rate, mild blood pressure increase); concurrent psychostimulants compound the cardiovascular burden.
* '''CYP interactions: not well characterized.''' Human metabolism of 2C-B has not been comprehensively studied. In vitro work suggests [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2D6|CYP2D6]] and [[Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP3A4|CYP3A4]] involvement; strong inhibitors of these enzymes may increase 2C-B exposure.
* '''CYP interactions: not well characterized.''' Human metabolism of 2C-B has not been comprehensively studied. In vitro work suggests [[Enzyme:CYP2D6|CYP2D6]] and [[Enzyme:CYP3A4|CYP3A4]] involvement; strong inhibitors of these enzymes may increase 2C-B exposure.


| pregnancy_details = Not characterized. 2C-B has not been studied in human pregnancy; no preclinical reproductive toxicology data are available in the public literature. The compound's Schedule I status precludes systematic study under conventional regulatory frameworks. Avoid in pregnancy on first-principles grounds.
| pregnancy_details = Not characterized. 2C-B has not been studied in human pregnancy; no preclinical reproductive toxicology data are available in the public literature. The compound's Schedule I status precludes systematic study under conventional regulatory frameworks. Avoid in pregnancy on first-principles grounds.